Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
A research vessel named Petrel has capsized in a dry dock in Leith, Edinburgh, causing injuries to 25 people.
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
MOSCOW: Ravil Maganov (chairman of Russia’s second-largest oil producer Lukoil) died today from a fall from a Moscow hospital window, according to Reuters.
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
While you may be enjoying your weekend, there is a chance that Covid will still be in your thoughts. Residents of Shanghai, a city with 25 million inhabitants, will spend
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test